Activity of alemtuzumab in patients with CD52-positive acute leukemia

Cancer

Volumn 106, Issue 12, 2006, Pages 2645-2651

  Tibes, Raoul ^a   Keating, Michael J ^a   Ferrajoli, Alessandra ^a   Wierda, William ^a   Ravandi, Farhad ^a   Garcia Manero, Guillermo ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a   Browning, Mary L ^a   Faderl, Stefan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Alemtuzumab; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; COTRIMOXAZOLE; DIPHENHYDRAMINE; FOSCARNET; GANCICLOVIR; MONOCLONAL ANTIBODY; PARACETAMOL; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; FUNGEMIA; HUMAN; INFECTION; KIDNEY FAILURE; LEUKEMIA REMISSION; MALE; MUCOSA INFLAMMATION; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RASH; RETINA HEMORRHAGE; RIGOR; SEIZURE; URTICARIA; VIRUS REACTIVATION; WEAKNESS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; BACTEREMIA; BONE MARROW; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FUNGEMIA; GLYCOPROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PNEUMONIA; TREATMENT OUTCOME;

EID: 33745190097     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21901     Document Type: Article

References (21)

1. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98:2095-2104.
2. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
3. Alcalay M, Orleth A, Sebastiani C, et al. Common themes in the pathogenesis of acute myeloid leukemia. Oncogene. 2001;20:5680-5694.
4. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer. 2003;89:1389-1394.
5. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs. 2003;17:147-154.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
7. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341-353.
8. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther. 2001;1:1059-1065.
9. Xia MQ, Tone M, Packman L, et al. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol. 1991;21:1677-1684.
10. Xia MQ, Hale G, Lifely MR, et al. Structure of the CAM-PATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J. 1993;293(pt 3):633-640.
11. Frampton JE, Wagstaff AJ. Alemtuzumab [review]. Drugs. 2003;63:1229-1243; discussion, 1245-1246.
12. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82: 807-812.
13. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99: 3554-3561.
14. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205-213.
15. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69-76.
16. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAM-PATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000; 96:2419-2425.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33: 451-458.
18. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
19. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia. 2004;18:1557-1558.
20. Piccaluga PP, Martinelli G, Malagola M, et al. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. Leuk Lymphoma. 2004;45:731-733.
21. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.